Corcept Therapeutics Inc
CORT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001088856
In the last 90 days, Corcept Therapeutics Inc insiders filed 0 open-market purchases and 17 sales; 425 institutions reported holding it in 13F filings for Q2 2026, worth $7.15B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $8.21B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $42.6M in total
- 17
- 13F holdersQ2 2026, +77 vs. previous quarter
- 425
- 13F valueReported value at the end of Q2 2026
- $7.15B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $761.4M
- +12.8% year over year
- Net income, FY2025
- $99.7M
- −29.4% year over year
- Free cash flow, FY2025
- $141.8M
- −27.6% year over year
- Revenue, Q3 FY2026
- $340.5M
- +64.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 8.59M
- Shares sold short
- Change
- +48.0K
- +0.6% vs. previous
- Days to cover
- 12.29
- At average daily volume
Superinvestors holding CORT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding CORT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Corcept Therapeutics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)7:26 PM ET | Nov 2-3 | 2 days | Maduck SeanOther: See Remarks | SSale | −25.0K | $81.85 | −$2.05M | −71.6%9.94K after | 3 lots10b5-1 |
| Nov 4, 2026 (view filing)7:20 PM ET | Nov 2 | 2 days | Vieira Roberto WandenkolkPresident, Oncology | SSale | −8.33K | $80.89 | −$674.1K | −67.9%3.95K after | 2 lots10b5-1 |
| Oct 16, 2026 (view filing)6:24 PM ET | Oct 15 | 1 day | Wilson James NDirector | SSale | −10.0K | $114.81 | −$1.15M | −0.9%1.05M after | 3 lots10b5-1 |
| Oct 5, 2026 (view filing)7:58 PM ET | Oct 2 | 3 days | Vieira Roberto WandenkolkPresident, Oncology | SSale | −8.33K | $116.10 | −$967.4K | −67.9%3.95K after | 3 lots10b5-1 |
| Oct 5, 2026 (view filing)7:54 PM ET | Oct 1-2 | 4 days | Lyon Joseph DouglasSee Remarks | SSale | −10.0K | $116.07 | −$1.16M | −63.8%5.68K after | 3 lots10b5-1 |
| Oct 5, 2026 (view filing)7:49 PM ET | Oct 1-2 | 4 days | Maduck SeanSee Remarks | SSale | −25.0K | $116.26 | −$2.91M | −71.6%9.94K after | 3 lots10b5-1 |
| Sep 18, 2026 (view filing)7:53 PM ET | Sep 16 | 2 days | Vieira Roberto WandenkolkPresident, Oncology | SSale | −296 | $100.82 | −$29.8K | −7.0%3.95K after | 10b5-1 |
| Sep 16, 2026 (view filing)4:30 PM ET | Sep 14 | 2 days | Lyon Joseph DouglasSee Remarks | SSale | −10.0K | $113.49 | −$1.13M | −63.8%5.68K after | 2 lots10b5-1 |
| Sep 16, 2026 (view filing)4:30 PM ET | Sep 15 | 1 day | Wilson James NDirector | SSale | −10.0K | $110.69 | −$1.11M | −0.9%1.06M after | 3 lots10b5-1 |
| Sep 3, 2026 (view filing)9:16 PM ET | Sep 1 | 2 days | Maduck SeanSee Remarks | SSale | −25.0K | $114.43 | −$2.86M | −71.9%9.76K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 425 holdersThe largest institutional positions in Corcept Therapeutics Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12,432,023 | $1.08B | 0.02% | +280,747+2.3% | Added |
| Ingalls & Snyder LLC | 7,934,507 | $689.9M | 18.85% | +325,791+4.3% | Added |
| Renaissance Technologies LLC | 5,261,628 | $457.5M | 0.63% | −421,155−7.4% | Reduced |
| Vanguard Portfolio Management LLC | 5,044,638 | $438.6M | 0.02% | +224,070+4.6% | Added |
| Vanguard Capital Management LLC | 4,172,482 | $362.8M | 0.01% | +95,286+2.3% | Added |
| Parallel Advisors, LLC | 3,962,177 | $344.5M | 5.26% | −15,227−0.4% | Reduced |
| FMR LLC | 3,337,618 | $290.2M | 0.01% | +147,426+4.6% | Added |
| State Street Corp | 3,279,381 | $285.2M | 0.01% | +78,435+2.5% | Added |
| AQR Capital Management LLC | 2,582,561 | $224.6M | 0.08% | +2,176,356+535.8% | Added |
| Geode Capital Management, LLC | 2,532,198 | $220.2M | 0.01% | −181,321−6.7% | Reduced |
Holders of 5% or more of CORT
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Corcept Therapeutics Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.90%9.61M shares | −2.00 ppfrom 10.90% | Apr 23, 20253 filings | Oct 27, 2026 | SEC |
| Ingalls & Snyder LLC | 13G/A | 6.80%7.26M shares | −1.00 ppfrom 7.80% | Feb 9, 20216 filings | Apr 21, 2026 | SEC |
| Belanoff Joseph K | 13G/A | 6.30%6.82M shares | – | Feb 11, 20215 filings | Feb 14, 2025 | SEC |